Metagenomi Therapeutics, Inc. (MGX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.72M | +52.3% |
| 2024 | $27.39M | -80.5% |
| 2023 | $140.60M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.72M | +52.3% |
| 2024 | $27.39M | -80.5% |
| 2023 | $140.60M | — |